LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

ENANTA PHARMACEUTICALS INC

Open

SectorHealthcare

7.5 3.45

Overview

Share price change

24h

Current

Min

7.04

Max

7.68

Key metrics

By Trading Economics

Income

-354K

-23M

Sales

-2M

15M

EPS

-1.06

Profit margin

-151.708

Employees

131

EBITDA

-1.2M

-21M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+128.19% upside

Dividends

By Dow Jones

Next Earnings

1 sie 2025

Market Stats

By TradingEconomics

Market Cap

34M

152M

Previous open

4.05

Previous close

7.5

News Sentiment

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

ENANTA PHARMACEUTICALS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 cze 2025, 23:49 UTC

Earnings

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 cze 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 cze 2025, 21:30 UTC

Earnings

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 cze 2025, 21:07 UTC

Earnings

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 cze 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 cze 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 cze 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 cze 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 cze 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 cze 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 cze 2025, 23:19 UTC

Acquisitions, Mergers, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 cze 2025, 22:06 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 cze 2025, 21:15 UTC

Earnings

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 cze 2025, 21:07 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 cze 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 cze 2025, 20:52 UTC

Earnings

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 cze 2025, 20:51 UTC

Earnings

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

128.19% upside

12 Months Forecast

Average 17 USD  128.19%

High 24 USD

Low 7 USD

Based on 3 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

5.04 / 5.44Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

154 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.